Literature DB >> 10854567

Is reoperation for recurrence of glioblastoma justified?

J Guyotat1, F Signorelli, D Frappaz, G Madarassy, A C Ricci, P Bret.   

Abstract

The purpose of the present study was to determine the effect of surgery on the time length and quality of survival in patients with recurrent glioblastoma multiforme. Two groups were compared; the first included 18 patients who underwent surgery at the time of tumour recurrence. The second group included 36 patients who did not undergo surgery at the time of tumour recurrence. Both groups were matched according to the following criteria: gender, age, Karnofsky Performance Scale (KPS) score, at the time of initial surgery and of tumour recurrence, extent of initial surgery, interval between initial surgery and tumour reccurence. Both groups received conventional treatment after initial surgery. There are no statistically significant differences between the two groups as regards to the previously mentioned criteria. After tumour recurrence, the median survival time was 5 months in the group of patients undergoing a second resection and 2 months in the group of patients not undergoing repeat surgery. The difference was statistically significant on univariate analysis. Moreover, the median length of time spent in an acceptable condition (KPS >/=60) from the time of tumour recurrence was found to be significantly longer in patient who underwent a second resection (4 months) compared with patients who did not undergo repeat surgery (1 month). Even in a relatively favorable subgroup of reoperated patients, the survival benefit although significant was only 3 months. It was impossible to completely match the two groups of patients suggesting that the difference might have been even less. Although symptomatic improvement is modestly achieved by repeat surgery, its transient nature necessitates clear discussion with patient and family on an individual basis.

Entities:  

Mesh:

Year:  2000        PMID: 10854567     DOI: 10.3892/or.7.4.899

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  26 in total

1.  Glioblastoma--the consequences of advanced patient age on treatment and survival.

Authors:  Andreas M Stark; Jürgen Hedderich; Janka Held-Feindt; H Maximilian Mehdorn
Journal:  Neurosurg Rev       Date:  2006-11-21       Impact factor: 3.042

2.  The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis.

Authors:  Debra A Goldman; Koos Hovinga; Anne S Reiner; Yoshua Esquenazi; Viviane Tabar; Katherine S Panageas
Journal:  J Neurosurg       Date:  2018-11-01       Impact factor: 5.115

3.  Novel Surgical Approaches to High-Grade Gliomas.

Authors:  Fahid Tariq Rasul; Colin Watts
Journal:  Curr Treat Options Neurol       Date:  2015-09       Impact factor: 3.598

4.  Should we reoperate for recurrent high-grade astrocytoma?

Authors:  Jin-fang Xu; Jun Fang; Yi Shen; Jian-min Zhang; Wei-guo Liu; Hong Shen
Journal:  J Neurooncol       Date:  2011-05-17       Impact factor: 4.130

5.  Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better.

Authors:  Joshua D Palmer; Joshua Siglin; Kosj Yamoah; Tu Dan; Colin E Champ; Voichita Bar-Ad; Maria Werner-Wasik; James J Evans; Lyndon Kim; Jon Glass; Christopher Farrell; David W Andrews; Wenyin Shi
Journal:  J Neurooncol       Date:  2015-05-30       Impact factor: 4.130

6.  Benefit of tumor resection for recurrent glioblastoma.

Authors:  Johanna Quick; Florian Gessler; Stephan Dützmann; Elke Hattingen; Patrick N Harter; Lutz M Weise; Kea Franz; Volker Seifert; Christian Senft
Journal:  J Neurooncol       Date:  2014-02-15       Impact factor: 4.130

7.  Feasibility and response to 1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride chemotherapy with pre-treated procarbazine for elderly patients with newly diagnosed glioblastoma.

Authors:  Mizuhiko Terasaki; Toshi Abe; Naohisa Miyagi; Etsuyo Ogo; Minoru Shigemori
Journal:  J Neurooncol       Date:  2006-08-26       Impact factor: 4.130

8.  Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?

Authors:  Amerigo Boiardi; Antonio Silvani; Marica Eoli; Elena Lamperti; Andrea Salmaggi; Paola Gaviani; Anna Fiumani; Andrea Botturi; Chiara Falcone; Alessandra Solari; Graziella Filippini; Francesco Di Meco; Giovanni Broggi
Journal:  J Neurooncol       Date:  2008-02-19       Impact factor: 4.130

9.  Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.

Authors:  Ayman I Omar; Warren P Mason
Journal:  Core Evid       Date:  2010-06-15

10.  Temozolomide in malignant glioma.

Authors:  Gregor Dresemann
Journal:  Onco Targets Ther       Date:  2010-09-07       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.